Strides Arcolab gets USFDA nod for cancer drug

NEW DELHI: Drug firm Strides Arcolab today said its subsidiary has received American health regulator's approval to sell Vinorelbine injection, a cancer drug, in the American market.

Onco Therapies Ltd, a wholly owned subsidiary of Strides Arcolab has received final approval from US Food and Drug Administration (USFDA) for Vinorelbine Injection, Strides said in a statement.

"Vinorelbine is part of the oncology portfolio licensed to Pfizer for the US market and the product is available for immediate launch," it added.

Vinorelbine is used to treat various types of cancers. It is a chemotherapy drug that works by slowing or stopping cancer cell growth.

Shares of Strides Arcolab were trading at Rs 819.50 on the BSE in late afternoon trade, down 1.21 per cent from its previous close.